Metastatic triple negative breast cancer
Conditions
Brief summary
Level of statistical agreement by means of Cohen’s kappa coefficient between PD-L1 IHC (positive defined as expression ≥1% on immune cells with SP142) and PD-L1 PET/CT (PD-L1 positivity is defined as having at least one lesion with radiotracer uptake over the background uptake).
Detailed description
Progression free survival, disease response rate and treatment discontinuation rates in three patient groups: 1. IHC positive and PET positive; 2. IHC positive and PET negative; 3. IHC negative and PET positive., Discordance in 89Zr-atezolizumab between different sites and within metastatic sites in the body., Progression free survival, disease response rate and treatment discontinuation rates in patients with ER-low mBC treated with nab-paclitaxel, carboplatin and atezolizumab., Percentage of 89Zr-atezolizumab uptake in sites, not previously determined on the routine radiological investigation with CT, as a measure of cancer spread determined on whole body 89Zr-atezolizumab PET/CT in and different metastases.
Interventions
DRUG(89Zr)Zr-Atezolizumab
DRUGCARBOPLATIN
DRUGAbraxane 5 mg/ml powder for dispersion for infusion.
Sponsors
Karolinska University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of statistical agreement by means of Cohen’s kappa coefficient between PD-L1 IHC (positive defined as expression ≥1% on immune cells with SP142) and PD-L1 PET/CT (PD-L1 positivity is defined as having at least one lesion with radiotracer uptake over the background uptake). | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, disease response rate and treatment discontinuation rates in three patient groups: 1. IHC positive and PET positive; 2. IHC positive and PET negative; 3. IHC negative and PET positive., Discordance in 89Zr-atezolizumab between different sites and within metastatic sites in the body., Progression free survival, disease response rate and treatment discontinuation rates in patients with ER-low mBC treated with nab-paclitaxel, carboplatin and atezolizumab., Percentage of 89Zr-atezolizumab uptake in sites, not previously determined on the routine radiological investigation with CT, as a measure of cancer spread determined on whole body 89Zr-atezolizumab PET/CT in and different metastases. | — |
Countries
Sweden
Outcome results
None listed